CCR 20th Anniversary Commentary: A Chimeric Antibody, C225, Inhibits EGFR Activation and Tumor Growth

被引：23

作者：

Mendelsohn, John ^{[1
]}

Prewett, Marie ^{[2
]}

Rockwell, Patricia ^{[3
]}

Goldstein, Neil I. ^{[4
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Eli Lilly & Co, Indianapolis, IN 46285 USA

[3] CUNY Hunter Coll, New York, NY 10021 USA

[4] Helio Genet, E Hanover, NJ USA

来源：

CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 02期

关键词：

RECEPTOR MONOCLONAL-ANTIBODY; METASTATIC COLORECTAL-CANCER; SQUAMOUS-CELL CARCINOMA; PHASE-I; CETUXIMAB; COMBINATION; RESISTANCE; NECK; HEAD;

D O I：

10.1158/1078-0432.CCR-14-2491

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Murine mAb 225 was effective against the EGFR tyrosine kinase and inhibited tumor growth in preclinical studies. A phase I trial showed safety, tumor localization, and satisfactory pharmacokinetics. Human: murine chimeric C225 retained biologic activity, which was essential for the conduct of subsequent combination therapy trials and eventual regulatory approval.

引用

页码：227 / 229

页数：3

共 37 条

[1] CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer
Mehra, Niven
Zafeiriou, Zafeiris
Lorente, David
Terstappen, Leon W. M. M.
de Bono, Johann S.
CLINICAL CANCER RESEARCH, 2015, 21 (22) : 4992 - 4995
[2] CCR 20th Anniversary Commentary: Paving the Way for Circulating Tumor Cells
Allard, W. Jeffrey
Terstappen, Leon W. M. M.
CLINICAL CANCER RESEARCH, 2015, 21 (13) : 2883 - 2885
[3] The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
Prewett, M
Rockwell, P
Rockwell, RF
Giorgio, NA
Mendelsohn, J
Scher, HI
Goldstein, NI
JOURNAL OF IMMUNOTHERAPY, 1996, 19 (06): : 419 - 427
[4] CCR 20th Anniversary Commentary: Chimeric Antigen Receptors-From Model T to the Tesla
Hwu, Patrick
CLINICAL CANCER RESEARCH, 2015, 21 (14) : 3099 - 3101
[5] CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341
Teicher, Beverly A.
Anderson, Kenneth C.
CLINICAL CANCER RESEARCH, 2015, 21 (05) : 939 - 941
[6] CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio
Bates, Susan E.
Robey, Robert W.
Piekarz, Richard L.
CLINICAL CANCER RESEARCH, 2015, 21 (10) : 2195 - 2197
[7] CCR 20th Anniversary Commentary: Prospects and Challenges of Therapeutic Nanoparticles in Cancer
Rahman, Mohammad Aminur
Shin, Dong M.
CLINICAL CANCER RESEARCH, 2015, 21 (20) : 4499 - 4501
[8] CCR 20th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping
Nielsen, Torsten O.
Perou, Charles M.
CLINICAL CANCER RESEARCH, 2015, 21 (08) : 1779 - 1781
[9] CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials
Carey, Lisa A.
CLINICAL CANCER RESEARCH, 2015, 21 (18) : 4027 - 4029
[10] CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy
Kelly, Wm Kevin
Marks, Paul
Richon, Victoria M.
CLINICAL CANCER RESEARCH, 2015, 21 (10) : 2198 - 2200

← 1 2 3 4 →